Communication Disorders: Clinical Trials

17 trials for Communication Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 3 unknown, 1 recruiting, 1 terminated. 17 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 417Completed 12, Unknown 3, Recruiting 1, Terminated 1

Follow Communication Disorders: new trials by email Literature Review of Communication Disorders trials Research Report on Communication Disorders

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Impact of Motor Tasks and Lidocaine on Reading Unfamiliar Words in Adults With and Without Dyslexia
Lidocaine 2% Polyampoule - Reading Disorders
Phase 4CompletedUniversity of Alberta562023-08-242026-02-05
Comparative Study Between Three Different Methods for Stuttering Therapy in Children
speech therapy only, hyperbaric oxygen therapy, medical treatment - Stuttering, Childhood
Phase 4UnknownSohag University302022-04-012022-03-22
Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine - Non-verbal Learning Disorder, Autism Spectrum Disorder
Phase 4CompletedMassachusetts General Hospital542019-05-202025-06-05
Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
AV-1451 - PPA, Non-fluent Aphasia
Phase 4RecruitingMayo Clinic502018-07-012025-11-12
A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging
Dexmedetomidine bolus and high infusion-Propofol, Dexmedetomidine bolus and low infusion-Propofol, Dexmedetomidine bolus only - Propofol - Epilepsy, Cerebral Palsy
Phase 4CompletedJoseph Cravero712017-03-022023-06-27
Interventions for Children With Attention and Reading Disorders
Methylphenidate, Intensive reading instruction, Parent Training - Attention Deficit Hyperactivity Disorder, Reading Disabilities
Phase 4CompletedThe University of Texas Health Science Center, Houston2222010-11-012017-04-11
Effects of Virtual Reality System in Children With Developmental Delays
virtual reality system - Developmental Delays
Phase 4CompletedRu-Lan Hsieh1572009-01-012014-07-09
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
Atomoxetine, Placebo - Attention Deficit Hyperactivity Disorder, Dyslexia
Phase 4CompletedEli Lilly and Company1102008-09-012022-11-04
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
Atomoxetine, Placebo - Attention Deficit Hyperactivity Disorder, Dyslexia
Phase 4CompletedEli Lilly and Company2092008-03-012011-12-15
Use of Sustained Release Antiepileptic Medication (Depakote® ER) for Pediatric Epilepsy in a Mental Retardation/Developmental Disorder Population
Swallow instruction - Epilepsy, Mental Retardation
Phase 4CompletedChildren's National Research Institute202005-08-012008-05-05
Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
Atomoxetine Hydrochloride, placebo - Attention Deficit Hyperactivity Disorder, Reading Disorder
Phase 4CompletedEli Lilly and Company1212005-04-012010-05-25
Memantine and Intensive Speech-Language Therapy in Aphasia
memantine, constraint-induced language therapy (CIAT), placebo - Aphasia, Stroke
Phase 4CompletedGabinete Berthier y Martínez282005-03-012008-03-21
Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial
memantine, constraint-induced language therapy - Aphasia, Stroke
Phase 4UnknownGabinete Berthier y Martínez302005-03-012005-09-20
Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia
Levodopa - Dyslexia
Phase 4UnknownUniversity Hospital Muenster1002005-01-012014-12-05
Dopaminergic Enhancement of Learning and Memory in Aphasia
levodopa - Cerebrovascular Accident, Aphasia
Phase 4CompletedUniversity Hospital Muenster122005-01-012013-10-07
Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial
Donepezil - Stroke, Aphasia
Phase 4CompletedGabinete Berthier y Martínez302003-02-012005-09-20
A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke
Piracetam, Placebo - Acute Ischaemic Middle Cerebral Artery Stroke
Phase 4TerminatedUCB S.A. - Pharma Sector5711998-08-012013-08-30

Narrower conditions

Aphasia (6)  ·  Dyslexia (6)  ·  Stroke (5)  ·  Attention Deficit Disorder with Hyperactivity (4)  ·  Learning Disabilities (4)  ·  Epilepsy (2)  ·  Aphasia, Broca (1)  ·  Aphasia, Primary Progressive (1)  ·  Apraxias (1)  ·  Autism Spectrum Disorder (1)  ·  Autistic Disorder (1)  ·  Cerebral Palsy (1)  ·  Developmental Disabilities (1)  ·  Intellectual Disability (1)  ·  Ischemia (1)

Broader conditions

Nervous System Diseases (17)  ·  Neurobehavioral Manifestations (17)  ·  Neurologic Manifestations (17)  ·  Pathological Conditions, Signs and Symptoms (17)  ·  Signs and Symptoms (17)  ·  Language Disorders (13)  ·  Mental Disorders (11)  ·  Neurodevelopmental Disorders (10)  ·  Brain Diseases (8)  ·  Central Nervous System Diseases (8)  ·  Speech Disorders (7)  ·  Learning Disabilities (6)  ·  Specific Learning Disorder (6)  ·  Cardiovascular Diseases (5)

Interventions

Atomoxetine Hydrochloride (4)  ·  Levodopa (2)  ·  Memantine (2)  ·  7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1)  ·  Acetylcysteine (1)  ·  Donepezil (1)  ·  Fatty Acids, Omega-3 (1)  ·  Guanfacine (1)  ·  Hyperbaric Oxygenation (1)  ·  Inositol (1)  ·  Lidocaine (1)  ·  Methylphenidate (1)  ·  Piracetam (1)

Sponsors

Eli Lilly and Company (3)  ·  Gabinete Berthier y Martínez (3)  ·  University Hospital Muenster (2)  ·  Children's National Research Institute (1)  ·  Joseph Cravero (1)  ·  Massachusetts General Hospital (1)  ·  Mayo Clinic (1)  ·  Ru-Lan Hsieh (1)  ·  Sohag University (1)  ·  The University of Texas Health Science Center, Houston (1)  ·  UCB S.A. - Pharma Sector (1)  ·  University of Alberta (1)

Countries

United States (7)  ·  Spain (4)  ·  Germany (3)  ·  Belgium (2)  ·  Taiwan (2)  ·  Argentina (1)  ·  Austria (1)  ·  Canada (1)  ·  France (1)  ·  Greece (1)  ·  Hungary (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Norway (1)  ·  Poland (1)

Top investigators

Marcelo L. Berthier, M.D., Ph.D (2)  ·  Carolyn A Denton, Ph.D. (1)  ·  Caterina Breitenstein, PhD (1)  ·  Janet Wozniak, MD (1)  ·  Jennifer Whitwell, PhD (1)  ·  Joan A Conry, MD (1)  ·  Joseph Cravero, MD (1)  ·  Marcelo L. Berthier, M.D., Ph.D. (1)  ·  Ru-Lan Hsieh, MD (1)  ·  Stefan Knecht, MD (1)  ·  Stefan Knecht, Prof. Dr. (1)

Results publications

PMID 25019647, PMID 20035588, PMID 24206099, PMID 25588456, PMID 26983099, PMID 27410907, PMID 27845858, PMID 33772416, PMID 42179727

NIH funding

2019 (1), R01DC012519 (1), R01HD060617 (1)